This is an expanded access designed to provide access to dasatinib for eligible participants.
Drug: Dasatinib
Local Institution
New York, New York, 10065
Investigator: Site 0024
Local Institution
Charlottesville, Virginia, 22908
Investigator: Site 003
Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb